重组组织型纤溶酶原激活剂对缺血性脑卒中患者LDH、NO、MDA、SOD的影响

Effect of recombinant tissue plasminogen activator on LDH,NO,MDA and SOD in patients with ischemic stroke

目的研究重组组织型纤溶酶原激活剂对缺血性脑卒中患者血清乳酸脱氢酶(LDH)、一氧化氮(NO)、丙二醛(MDA)、超氧化物歧化酶(SOD)的影响。方法选取2012年3月至2018年8月来该院治疗的86例缺血性脑卒中患者为研究对象,将其分为对照组和治疗组,每组43例,治疗组采用重组组织型纤溶酶原激活剂结合阿司匹林治疗,对照组采用阿司匹林治疗。比较治疗后2组患者的临床疗效,检测血清LDH、NO、MDA、SOD水平。结果治疗组总有效率(90.70%)高于对照组(62.80%),LDH、NO、MDA水平低于对照组,SOD水平高于对照组,差异有统计学意义(P<0.05)。治疗后,治疗组基本痊愈、显效及有效患者的血清LDH、NO及MDA水平低于对照组,SOD水平高于对照组,差异有统计学意义(P<0.05)。随着临床疗效的逐渐增强,患者血清中LDH、NO、MDA水平降低,SOD水平升高,且差异有统计学意义(P<0.05)。结论重组组织型纤溶酶原激活剂对缺血性脑卒中患者有显著的临床治疗效果。

Objective To study the effect of recombinant tissue plasminogen activator on serum lactate dehydrogenase(LDH),nitric oxide(NO),malondialdehyde(MDA)and superoxide dismutase(SOD)in patients with ischemic stroke.Methods Eighty-six patients with ischemic stroke in the hospital from March 2012 to August 2018 were divided into control group and treatment group,43 cases in each group.The treatment group was treated with recombinant tissue plasminogen activator combined with aspirin,while the control group was treated with aspirin.After treatment,the clinical efficacy of the two groups was compared,and the levels of serum LDH,NO,MDA and SOD were detected.Results The total effective rate of the treatment group(90.70%)was significantly higher than that of the control group(62.80%),the levels of LDH,NO and MDA were significantly lower than those of the control group,and the level of SOD was significantly higher than that of the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of LDH,NO and MDA in the treatment group were significantly lower than those in the control group,and the level of SOD in the treatment group was significantly higher than that in the control group,and the differences were statistically significant(P<0.05).With the gradual enhancement of clinical efficacy,the levels of LDH,NO and MDA in the serum of patients were decreased,and the level of SOD was increased,and the differences were statistically significant(P<0.05).Conclusion Recombinant tissue plasminogen activator has a significant clinical therapeutic effect on patients with ischemic stroke.